Browse current and past press releases from The Michael J. Fox Foundation.
December 02, 2014
Fellowship Program Building a Workforce of Parkinson's Disease Care and Research Specialists
The Michael J. Fox Foundation for Parkinson's Research, in collaboration with its longtime supporter and partner The Edmond J. Safra Foundation, announces The Edmond J. Safra Fellowship in Movement Disorders. By increasing resources for specialized training for clinician-researcher neurologists, the program aims to grow the global base of movement disorder specialists treating people with Parkinson's di...Read More
The Michael J. Fox Foundation Forms New Partnership with The Bachmann-Strauss Dystonia and Parkinson's Foundation
September 17, 2014
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Bachmann-Strauss Dystonia and Parkinson Foundation (BSDPF) announced today a new collaborative research alliance to facilitate greater visibility and deeper investment in advancing dystonia and Parkinson's research. The partnership establishes a major dystonia research prize to expand public awareness, acknowledge key scientific discoveries and incentivize the work of dedicated researchers in dystonia, an under-funded movement...Read More
September 09, 2014
NEW YORK, NY, September 9, 2014 - A recent survey of more than 1,500 Parkinson's disease (PD) patients, caregivers and physicians reveals that information and specialized care can help patients become more engaged in their own treatment and in the Parkinson's community.
"When patients get to the right doctor, it often leads to better optimization of care, greater engagement in the Parkinson's community, and more participation in clinical research critical to developing treatments," said Debor...Read More
The Michael J. Fox Foundation and Intel Join Forces to Improve Parkinson's Disease Monitoring and Treatment through Advanced Technologies
August 13, 2014
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Intel Corporation announced today a collaboration aimed at improving research and treatment for Parkinson's disease -- a neurodegenerative brain disease second only to Alzheimer's in worldwide prevalence. The collaboration includes a multiphase research study using a new big data analytics platform that detects patterns in participant data collected from wearable technologies used to monitor symptoms. This effort is an important s...Read More
Promising Parkinson's Disease Research Highlighted by The Michael J. Fox Foundation to Accelerate Drug Development
August 12, 2014
Research projects from five groups active in Parkinson's research comprise the 2014 first half (1H 2014) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program projects are presented directly to industry groups who may wish to invest in further development. By connecting industry leaders with those studies ripe for investment, the Foundation aims to drive forward promising research in Parkinson's dis...Read More
August 05, 2014
Researchers need to know the genetic profiles of their study participants to understand more about how certain mutations manifest disease. But do the participants have to know?
A group of 35 Parkinson's disease (PD) researchers published today in Genetics of Medicine the different answers to that question among sites investigating mutations in the LRRK2 gene, the greatest known genetic contributor to PD. Investigators from The Michael J. Fox Foundation-sponsored LRRK2 Cohort Consortium authored...Read More
July 31, 2014
NEW YORK and VIENNA, Austria - AFFiRiS AG announced today at a press conference in New York results of AFF008, a Phase I clinical trial of PD01A, a vaccine against Parkinson's disease. PD01A is the first therapy against the protein alpha-synuclein, a promising Parkinson's drug target, to enter clinical testing.
The Michael J. Fox Foundation for Parkinson's Research (MJFF) supported the study with a $1.5 million grant, and presented at the press conference on the impact a disease-modifying ther...Read More
RaceTrac Reaches $1 Million Milestone in Giving to The Michael J. Fox Foundation for Parkinson's Research
July 28, 2014
Atlanta, GA - July 28, 2014 -RaceTrac announced that its cumulative giving to The Michael J. Fox Foundation for Parkinson's Research has exceeded $1 million. This milestone is due in large part to the continued efforts of their team members who have executed various initiatives over the years encouraging the community to participate in and support a worthy cause.
"In four short years, RaceTrac has shown incredible generosity and commitment not only financially supporting our mission, but also hel...
Parkinson's Organizations Unite to Serve Patients and Families Through National "Partners in Parkinson's" Initiative
July 22, 2014
NEW YORK, NY, July 22, 2014 - National Parkinson's organizations are working together to help provide Parkinson's patients and caregivers with knowledge and support to optimize their care through the "Partners in Parkinson's" strategic health initiative launched by The Michael J. Fox Foundation and AbbVie.
Partners in Parkinson's offers Parkinson's disease (PD) patients and caregivers virtual and face-to-face opportunities to connect with knowledge, tools and support to optimize care from diagn...Read More
Leading Foundations Publish Recommendations to Accelerate Drug Repurposing for Neurodegenerative Diseases
June 26, 2014
A new peer-reviewed publication from the Alzheimer's Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson's Research (MJFF) offers strategic insight on how philanthropy, industry and government organizations can advance repurposing of U.S. Food and Drug Administration (FDA)-approved drugs for the treatment of neurodegenerative diseases. The paper, published in the Annals of Clinical and Translational Neurology, was produced in collaboration with experts from these sec...Read More
May 27, 2014
NEW YORK, NY, May 27, 2014 -The Michael J. Fox Foundation (MJFF) and AbbVie announced the launch of Partners in Parkinson's, a new strategic health initiative offering comprehensive support to help people with Parkinson's disease (PD) optimize their care at every stage of the disease.
"No two cases of Parkinson's disease are alike. Patients and caregivers need high-quality, trustworthy information and resources that can help navigate a Parkinson's diagnosis and progression," said Todd Sherer, P...Read More
April 23, 2014
The Michael J. Fox Foundation for Parkinson's Research (MJFF) is launching a new funding program to promote collaborative analysis of subtypes of the protein alpha-synuclein.
Aggregating in the cells of all people with Parkinson's disease (PD), alpha-synuclein is a major target for drug development. To advance those efforts, scientists must analyze different species of this protein -- resulting from splicing or post-translational modifications -- to name those implicated in the pathological ac...Read More
Heiko Braak, MD, Author of Parkinson's Staging Procedure, Honored with 2014 Robert A. Pritzker Prize
April 22, 2014
Heiko Braak, MD, who proposed a novel pathway of Parkinson's disease progression, is the recipient of the 2014 Robert A. Pritzker Prize for Leadership in Parkinson's Research, conferred annually by The Michael J. Fox Foundation for Parkinson's Research (MJFF).
In 2003, Braak -- now senior professor at Ulm University in Germany -- outlined a Parkinson's staging system, which describes the regional distribution and progression of protein aggregates in the brain. The same year, Braak theorized tha...Read More
March 31, 2014
Results out of a study funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) have enabled researchers to secure a $23 million grant from the National Institutes of Health (NIH), continuing a repurposed drug approved for hypertension to Phase III testing for slowing Parkinson's progression. The trial investigating the compound isradipine will be the most advanced, current study into a disease-modifying therapy for Parkinson's, an unmet need.
Isradipine is a calcium channel bloc...Read More
February 25, 2014
NEW YORK - The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF), is expanding to study individuals with genetic mutations associated with Parkinson's disease (PD). Researchers hope that greater understanding of the biology and clinical features of these participants -- people with or at risk to develop Parkinson's -- will lead to therapeutics that would help all Parkinson's patients and ult...Read More
February 20, 2014
NEW YORK - As medical researchers across disease states pursue better treatments, they all share one limiting factor. Estimates hold that 85 percent of all studies face delays and 30 percent never get off the ground due to a lack of clinical research volunteers. Slow patient enrollment diminishes the scientific power of studies, drives costs up and, most notably, delays improved therapies for patients.
Partnership of patients and scientists in clinical research -- not only implementation, but a...Read More
February 05, 2014
CHICAGO, NEW YORK, TORONTO - As research unveils overlap in the biology -- in addition to long-noted shared clinical symptoms -- of Parkinson's and Alzheimer's diseases, three non-profit organizations are uniting to encourage further study into the similarities and differences between the two most common brain diseases, which affect tens of millions of people worldwide.
The Michael J. Fox Foundation for Parkinson's Research (MJFF), the Alzheimer's Association and The W. Garfield Weston Foundati...Read More